Blood Circulation Supplements: An Honest, Evidence-Graded Guide

Key Takeaways:

• No supplement is a substitute for movement, medication when prescribed, or treating an underlying condition. That said, several have real human evidence for circulation-related measures.
• Best-supported options: omega-3s for triglycerides (strong), then garlic, beetroot, magnesium, vitamin K2 (MK-7), and nattokinase, each with moderate evidence for blood pressure or arterial-health measures.
• Skip ginkgo. A Cochrane review of 14 trials found no clinically significant benefit for leg circulation.
• Avoid high-dose niacin and high-dose vitamin E unless a doctor prescribes them. Large trials and NIH reviews link them to serious risks, not benefits.
• Talk to your physician first if you take any anticoagulant or antiplatelet medication. Several supplements on this list affect clotting pathways.

Search for circulation supplements, and you’re likely to find lists that grade everything a winner. This guide does the opposite. We graded each option strictly on human evidence, flagged the study designs and their limits, and included the supplements you should skip. One of them is popular, and two of them carry real risk.

If you’re still figuring out whether circulation is your actual issue, start with our guide to signs of poor circulation. And because no powder or pill outperforms daily habits, pair anything below with the basics on how to improve circulation naturally.

How Did We Grade These Supplements?

Every supplement below gets one of five grades based on the strength of its human evidence, not its popularity:

• Strong: Consistent results across many randomized controlled trials (RCTs)
• Moderate: Positive RCT or meta-analysis evidence with limitations (small samples, short duration, or funding concerns we name)
• Preliminary: Promising but early; results need replication in controlled trials
• Null: Tested properly and did not deliver a meaningful benefit
• Caution: Evidence points to risk, not benefit

Here’s the whole guide at a glance:

Which Supplements Have the Best Evidence for Blood Circulation?

Eight supplements have credible human research for circulation-related measures. Here’s each one, and how we grade it.

Omega-3 Fatty Acids: Strong for Triglycerides

Omega-3s have the strongest single finding on this list. According to the NIH Office of Dietary Supplements, the American Heart Association concludes that 4 g/day of prescription omega-3s lowers triglycerides, and an analysis of 58 trials found each 1 g/day of long-chain omega-3s reduces triglycerides by about 5.9 mg/dL.

That said, though, there is a caveat. Evidence for hard cardiovascular outcomes (heart attacks, strokes) is mixed. Because of that, we grade omega-3s as strong for triglycerides, but unresolved for everything else.

Garlic: Moderate, With a Funding Caveat

Garlic posted the largest blood pressure numbers in our review. A 2020 meta-analysis of 12 trials in 553 adults with hypertension (Ried, Experimental and Therapeutic Medicine) found aged garlic extract reduced systolic blood pressure by 8.3 +/- 1.9 mmHg and diastolic by 5.5 +/- 1.9 mmHg in responders, with improved arterial stiffness.

So, why not grade it as strong? The reality is that nearly all of those trials came from a single industry-funded research program using one branded aged garlic extract (Kyolic). The results are consistent, but independent replication is thin.

Beetroot and Dietary Nitrate: Moderate Short-Term

Beetroot works through a clear mechanism: dietary nitrate converts to nitrite and then to nitric oxide, which relaxes blood vessels. A 16-trial review (Siervo et al., Journal of Nutrition, 2013) found systolic reductions of about 4.4 mmHg, and a 2022 meta-analysis in hypertensive patients found clinic systolic readings dropped about 5.3 mmHg, but with no significant effect on 24-hour ambulatory pressure.

Put simply, beetroot can reliably have benefits for a few hours. Whether it produces durable, around-the-clock change, though, is what’s unclear. We grade it as moderate for short-term effects.

Vitamin K2 (MK-7): Moderate for Arterial Stiffness

Two very different studies support K2, and they deserve different weights. The Rotterdam Study followed 4,807 adults for roughly 7 to 10 years and found the highest tertile of dietary K2 intake was associated with a 57% lower relative risk of coronary heart disease mortality (RR 0.43) and 52% lower odds of severe aortic calcification; vitamin K1 showed no association (Geleijnse et al., Journal of Nutrition, 2004). That’s observational: it shows association, but not causation.

The stronger design is a 3-year double-blind RCT in 244 healthy postmenopausal women: 180 mcg/day of MK-7 improved pulse wave velocity and stiffness index versus placebo and cut inactive matrix Gla protein (dp-ucMGP) by about 50% (Knapen et al., Thrombosis and Haemostasis, 2015).

We grade vitamin K2 as moderate.

Magnesium: Moderate, Small but Consistent

Magnesium's effect is modest and unusually well replicated. A meta-analysis of 34 RCTs with 2,028 participants (median dose 368 mg/day for 3 months) found systolic reductions of 2.0 mmHg and diastolic reductions of 1.78 mmHg (Zhang et al., Hypertension, 2016). These may be small numbers, but 34 trials all pointing in the same direction earns a moderate grade in our books.

Nattokinase: Moderate for Blood Pressure, Preliminary for the Rest

Nattokinase is the enzyme this site covers most, so we will hold it to the same standard as everything above. It is a fibrinolytic serine protease first isolated from the fermented soy food natto in 1987; mechanistic research shows nattokinase degrades cross-linked fibrin directly and enhances tissue plasminogen activator activity (Chen et al., Biomarker Insights, 2018).

Mechanism is established in the lab. Human evidence is where nattokinase grading matters:

• Blood pressure, moderate: An 8-week randomized, double-blind, placebo-controlled trial (86 enrolled, 73 completed) found 2,000 FU/day reduced systolic pressure by 5.55 mmHg and diastolic by 2.84 mmHg versus placebo (Kim et al., Hypertension Research, 2008). A 2023 systematic review and meta-analysis of 6 RCTs (546 participants) confirmed a modest effect: -3.45 mmHg systolic, -2.32 mmHg diastolic, while flagging small samples and dose heterogeneity. The same review found no significant lipid effect at common doses.
• Lipids and arterial plaque, preliminary: A 12-month study of 10,800 FU/day in 1,062 participants reported improved lipid profiles and reduced carotid intima-media thickness and plaque size, with improvement rates of 66.5% to 95.4% and no notable adverse events; a lower 3,600 FU/day dose showed no benefit (Chen et al., Frontiers in Cardiovascular Medicine, 2022). This was an open-label study without a randomized placebo control, and it was published with a later corrigendum. Those results are promising and dose-dependent, but they are not RCT-grade.

For a deeper look at the mechanism and the full research base, explore our walkthrough of nattokinase benefits based on what the research actually shows.

Cocoa Flavanols: Moderate but Mixed

Cocoa flavanols got the biggest trial on this list, and the result was mixed. The COSMOS RCT randomized 21,442 adults aged 60+ to 500 mg/day of cocoa flavanols for 3.6 years. It missed its primary endpoint of total cardiovascular events (HR 0.90, p=0.11) but found a 27% reduction in cardiovascular death as a secondary endpoint (HR 0.73) (Sesso et al., American Journal of Clinical Nutrition, 2022). Both facts matter; honest guides report both.

It’s also important to note the regulatory framing here: in February 2023, the FDA issued a qualified health claim, under enforcement discretion, that cocoa flavanols in high-flavanol cocoa powder "may reduce the risk of cardiovascular disease" with "very limited scientific evidence." That applies to high-flavanol cocoa powder only. Chocolate does not qualify.

L-Citrulline: Preliminary and Inconsistent

L-citrulline feeds the same nitric oxide pathway as beetroot, and early results looked similar: a 2019 meta-analysis of 8 RCTs found systolic reductions of roughly 4 mmHg, with diastolic effects mainly at doses above 5 g/day (Barkhidarian et al., Avicenna Journal of Phytomedicine, 2019). But other research updates conclude the evidence remains inconsistent and underpowered. Preliminary. This one is worth watching, but not yet worth building a routine around.

Which Popular Supplement Should You Skip?

Ginkgo biloba, and this is exactly where most roundups lose credibility by hedging. A Cochrane review of 14 trials covering 739 participants with peripheral artery disease found ginkgo added 64.5 meters of walking distance versus placebo and concluded there is "no evidence that Ginkgo biloba has a clinically significant benefit" for peripheral artery disease (Nicolai et al., Cochrane Database of Systematic Reviews, 2013).

Grade: null. Ginkgo was tested properly, but it did not deliver. Ginkgo also interacts with blood thinners (see the safety section below), so you would be taking on risk for no established circulation benefit.

Which Supplements Carry Real Risk When It Comes to Blood Circulation?

Two supplements sometimes marketed for circulation have evidence pointing the wrong way.

The first of these two is high-dose niacin. The HPS2-THRIVE trial randomized 25,673 statin-treated patients to extended-release niacin. It added no reduction in major vascular events and increased serious adverse events: new-onset diabetes in 9.1% versus 7.3%, and bleeding in 2.5% versus 1.9% (New England Journal of Medicine, 2014). That’s strong evidence against high-dose supplemental niacin. If a doctor prescribes niacin, that’s their call, but don’t self-supplement high doses.

The second supplement in question here is high-dose vitamin E. The NIH Office of Dietary Supplements warns that high-dose vitamin E supplementation can increase bleeding risk, and two trials found an increase in hemorrhagic stroke. The tolerable upper intake level is 1,000 mg/day. Grade: caution.

Can You Take Circulation Supplements With Blood Thinners?

It’s important not to take circulation supplements alongside blood thinners without your physician's supervision.

Several supplements in this guide act on clotting or platelet pathways, which is exactly why they can be dangerous when used alongside anticoagulant or antiplatelet medication:

• The NCCIH reports that ginkgo combined with warfarin is associated with increased major bleeding, and that concentrated garlic inhibits platelet aggregation and can potentiate blood thinners.
• Nattokinase is fibrinolytic by mechanism. Do not combine it with anticoagulants or antiplatelet drugs without physician supervision.
• Vitamin K2 antagonizes warfarin, which works by blocking vitamin K.
• It’s always best to tell your entire care team about every supplement you take if you are on warfarin.

If you take warfarin, a DOAC, aspirin therapy, clopidogrel, or any prescription that affects clotting or blood pressure, bring this list to your doctor before starting anything on it.

The Bottom Line: Evidence First, Supplements Second

If you remember one thing: supplements are the third lever, after movement and after addressing underlying causes with your doctor. Within that honest frame, the evidence supports omega-3s for triglycerides, and garlic, beetroot, magnesium, K2, and nattokinase as moderately supported options for blood pressure and arterial health. Skip ginkgo. Avoid high-dose niacin and vitamin E. Clear everything with your physician if you take blood thinners.

We built Toku Flow around two of the graded options above: 10,800 FU of nattokinase (the dose from the 12-month open-label study) plus vitamin K2 (MK-7) and oat beta-glucan, in a single powdered drink.

See How Toku Flow Is Formulated

*The information provided in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives. This content has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Keep out of reach of children. Consult with your physician before use if you are pregnant, nursing, have a medical condition, or are taking anticoagulants or blood pressure medications. Discontinue use and consult with your health care professional if you experience any adverse reaction to this product.

Sources:

1. Chen et al., "Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases," Biomarker Insights, 2018. https://pubmed.ncbi.nlm.nih.gov/30013308/
2. Kim et al., nattokinase blood pressure RCT, Hypertension Research, 2008. https://pubmed.ncbi.nlm.nih.gov/18971533/
3. Systematic review and meta-analysis of nattokinase RCTs, Reviews in Cardiovascular Medicine, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11266782/
4. Chen et al., 12-month open-label study of nattokinase 10,800 FU/day, Frontiers in Cardiovascular Medicine, 2022 (published with corrigendum). https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.964977/full
5. Geleijnse et al., Rotterdam Study, Journal of Nutrition, 2004. https://www.sciencedirect.com/science/article/pii/S0022316623028961
6. Knapen et al., MK-7 and arterial stiffness RCT, Thrombosis and Haemostasis, 2015. https://cris.maastrichtuniversity.nl/en/publications/menaquinone-7-supplementation-improves-arterial-stiffness-in-heal/
7. NIH Office of Dietary Supplements, Omega-3 Fatty Acids fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
8. Barkhidarian et al., L-citrulline meta-analysis, Avicenna Journal of Phytomedicine, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369322/
9. L-citrulline evidence update, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11053694/
10. Siervo et al., dietary nitrate and blood pressure review, Journal of Nutrition, 2013. https://pubmed.ncbi.nlm.nih.gov/23596162/
11. Beetroot meta-analysis in hypertensive patients, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965354/
12. Sesso et al., COSMOS trial, American Journal of Clinical Nutrition, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170467/
13. FDA qualified health claim announcement, cocoa flavanols, February 3, 2023. https://www.fda.gov/food/hfp-constituent-updates/fda-announces-qualified-health-claim-cocoa-flavanols-high-flavanol-cocoa-powder-and-reduced-risk
14. Ried, aged garlic extract meta-analysis, Experimental and Therapeutic Medicine, 2020. https://pubmed.ncbi.nlm.nih.gov/32010325/
15. Nicolai et al., Ginkgo biloba for intermittent claudication, Cochrane Database of Systematic Reviews, 2013 (CD006888). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006888.pub3/abstract
16. Zhang et al., magnesium and blood pressure meta-analysis, Hypertension, 2016. https://www.ahajournals.org/doi/10.1161/hypertensionaha.116.07664
17. HPS2-THRIVE Collaborative Group, New England Journal of Medicine, 2014. https://www.nejm.org/doi/full/10.1056/NEJMoa1300955
18. NIH Office of Dietary Supplements, Vitamin E fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/
19. Cleveland Clinic: iron deficiency anemia, vitamin deficiency anemia, vitamin B12 deficiency. https://my.clevelandclinic.org/health/diseases/22824-iron-deficiency-anemia, https://my.clevelandclinic.org/health/diseases/17732-vitamin-deficiency-anemia, https://my.clevelandclinic.org/health/diseases/22831-vitamin-b12-deficiency
20. NCCIH, herb-drug interactions digest. https://www.nccih.nih.gov/health/providers/digest/herb-drug-interactions
21. Mayo Clinic, warfarin side effects and supplement disclosure. https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/in-depth/warfarin-side-effects/art-20047592